are our inspiration
Home / People / NOMIS Researcher / Marc-David Ruepp

Marc-David Ruepp

Marc-David Ruepp

Marc-David Ruepp is a reader in RNA biology and molecular neurodegeneration at King’s College London and a group leader at the UK Dementia Research Institute. He led the Elucidation of Selective Motor Neuron Death in Amyotrophic Lateral Sclerosis (ALS) project and is now co-leading the Elucidating the Mechanisms of FUS-Linked ALS project.

Born in Switzerland, Ruepp studied biochemistry at the University of Bern (Switzerland). He received an MSc in biochemistry in 2005 and then went on to pursue an interfaculty PhD in the Graduate School for Cellular and Biomedical Sciences at the University of Bern. He received a PhD (summa cum laude) in 2009 and completed postdoctoral work in the Department of Chemistry and Biochemistry. He started his own research group as junior group leader in 2014, joined the Swiss National Centre of Competence in Research “RNA and Disease” as junior PI in 2017 and obtained the Venia Docendi in RNA biology in 2018. He then moved to London to take up a position as senior lecturer in neuroscience at King’s College London and group leader at the UK Dementia Research Institute. He was promoted to reader in RNA biology and molecular neurodegeneration in August 2022.

Ruepp’s research focuses on dysfunctional RNA metabolism in neurodegeneration with a specific focus on amyotrophic lateral sclerosis, frontotemporal dementia and spinal muscular atrophy. Inter alia, his work led to the discovery that fused in sarcoma (FUS) regulates minor intron splicing and that this process is affected by ALS-causing mutations, thereby discovering a common pathomechanism with spinal muscular atrophy and highlighting the role of minor intron splicing defects in neurological disorders. In addition to studying fundamental disease processes, the lab also works toward translation by using gained insights to develop new therapeutic approaches.

Marc-David Ruepp | Awards Film

Marc-David Ruepp | Insights Film

Marc-David Ruepp's News

Jonas Mechtersheimer and Daniel Jutzi, students in the research laboratory of NOMIS scientist Marc-David Ruepp, obtained their PhDs in molecular biology on May 1, 2020, and September 1, 2020, respectively, […]

Marc-David Ruepp's Insights

Abstract: Pharmacologic depletion of RNA-binding motif 39 (RBM39) using aryl sulfonamides represents a promising anti-cancer therapy but requires high levels of the adaptor protein DCAF15. Consequently, novel approaches to deplete RBM39 in an DCAF15-independent manner are required. Here, we uncover that RBM39 autoregulates via the inclusion of a poison exon into